PDF-(READ)-The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence

Significant changes have taken place in the policy landscape surrounding cannabis legalization production and use During the past 20 years 25 states and the District of Columbia have legalized cannabis andor cannabidiol a component of cannabis for medical conditions or retail sales at the state level and 4 states have legalized both the medical and recreational use of cannabis These landmark changes in policy have impacted cannabis use patterns and perceived levels of riskHowever despite this changing landscape evidence regarding the short and longterm health effects of cannabis use remains elusive While a myriad of studies have examined cannabis use in all its various forms often these research conclusions are not appropriately synthesized translated for or communicated to policy makers health care providers state health officials or other stakeholders who have been charged with influencing and enacting policies procedures and laws related to cannabis use Unlike other controlled substances such as alcohol or tobacco no accepted standards for safe use or appropriate dose are available to help guide individuals as they make choices regarding the issues of if when where and how to use cannabis safely and in regard to therapeutic uses effectivelyShifting public sentiment conflicting and impeded scientific research and legislative battles have fueled the debate about what if any harms or benefits can be attributed to the use of cannabis or its derivatives and this lack of aggregated knowledge has broad public health implications The Health Effects of Cannabis and Cannabinoids provides a comprehensive review of scientific evidence related to the health effects and potential therapeutic benefits of cannabis This report provides a research agendaa outlining gaps in current knowledge and opportunities for providing additional insight into these issuesa that summarizes and prioritizes pressing research needs. Presented by: Candice Beathard, PhD. December 15, 2015 . Background: History of Cannabis as Medicine . Dates back to 2727B.C. in China. 1. In U.S…. 1850: cannabis tinctures patented. 2. . 1963: chemical structure of cannabis identified. This program will include a discussion of investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. Gregg VandeKieft, MD, MA. WSHPCO “Expanding dimensions in hospice & palliative care”. Chelan, . wa. October 10, 2017. Disclosure. Dr. VandeKieft does not have any conflicts of interest to disclose. He will discuss medical applications of cannabis, but will not discuss off-label use of medications.. Christopher Campbell. PGY2 Pediatric Pharmacy Resident. Augusta University Medical Center . University of Georgia College of Pharmacy. Disclosure. I do not have (nor does any immediate family member have) actual or potential conflict of interest, within the last twelve . Learning Objectives . Review the New Mexico Cannabis Program.. Describe how cannabis works in the body.. Identify available dosage forms and their benefits and cautions. . Identify common adverse effects of medical cannabis use.. May 11. th. 2018. CTN Agenda . 2.  .  .  .  . 2018 Spring Education Conference. May 11. th. 2018. Location:  Swedish Medical Center Conference Center.  . 8:30 Registration/Light Breakfast provided by CTN. 2 nd Annual Spring Conference May 11 th 2018 CTN Agenda 2         2018 Spring Education Conference May 11 th 2018 Location:  Swedish Medical Center Conference Center   8:30 Registration/Light Breakfast provided by CTN Current State of Evidence and Recommendations for Research. This report . is available to download . as a free . pdf:. N. ationalacademies.org/. CannabisHealthEffects. Outline of Presentation. Brief overview of study context and statement of task. “Medicinal Marijuana” is being used as a smokescreen for allowing recreational dope Politicians are considering the issue of medicinal marijuana e Labour-led government is focusing on t Stephanie Abel, PharmD, BCPS. Pain Management and Palliative Care Clinical Pharmacy Specialist. The Ohio State University Wexner Medical Center – James Cancer Hospital. Appointed Member – Ohio Medical Marijuana Advisory Committee. Jeanette M. Tetrault, MD FACP FASAM. Professor of Medicine. Program Director, Addiction Medicine Fellowship. Associate Director for Education and Training, . Program in Addiction Medicine. Yale School of Medicine. Special Content Expert on Cannabis. Division of Therapeutics & Medical Consequences . National Institute on Drug Abuse. . aidan.hampson@nih.gov. Disclosures:. Any opinions expressed are my own and may/not represent an official position of the National Institute on Drug Abuse.. Bill Griesar, Ph.D.. Neuroscience, WSU Vancouver. Psychology, Portland State University. Behavioral Neuroscience, OHSU. NW Noggin. Jeff Leake, M.F.A.. Neuroscience, WSU Vancouver. NW Noggin. Ram Kandasamy. Jeanette M. Tetrault, MD FACP FASAM. Associate Professor of Medicine. Program Director, Addiction Medicine Fellowship. Associate Director for Education and Training, Program in Addiction Medicine. Yale School of Medicine.